Analysis-Trump's Tylenol Claims Limit M&A Options for Parent Company Kenvue By Abigail Summerville and Svea Herbst-Bayliss (Reuters) -Tylenol maker Kenvue was already having a painful year before U.S.

Kenvue faces investor pressure amid strategic review, leadership changes and litigation risk Trump administration position on Tylenol erased $10 billion in market value Potential sale or spin-off of ...

(Reuters) -Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved. Activist investor Starboard Value took aim at the company ...